Artelo’s Cancer Drug Shows Promise in Phase 2 CARES Trial
Artelo’s interim Phase 2 readout in cancer anorexia-cachexia syndrome (CACS) shows patients titrated to 1300 micrograms of ART27.13 gained...
Jon Napitupulu
Ascendis to Share New Rare Disease Endocrinology Data
Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning...
New Hope: Alpha Tau Treats First Pancreatic Cancer Patient
Alpha Tau has treated the first patient in IMPACT, a U.S. multi-center pilot evaluating intratumoral Alpha DaRT in combination...
Neuro Tech Triumph: Vielight Powers Sports Champions
Season-long analyses in collegiate football athletes reported decreases in diffusion MRI markers associated with neuroinflammation among players using Vielight’s...
Rezolute Aligns With FDA on Streamlined Ersodetug Trial
Rezolute secured FDA alignment to convert its ongoing upLIFT study of ersodetug in tumor-associated hyperinsulinism into a single‑arm, open‑label...
Jade Biosciences Doses First Cohort in JADE101 Phase 1 Trial
Jade Biosciences has begun dosing in a randomized, double-blind, placebo-controlled Phase 1 study of JADE101, a subcutaneous, fully human...
New Vascepa Data Shows Reduced CVD Risk, Hospitalizations
Among REDUCE-IT participants with cardiovascular-kidney-metabolic (CKM) syndrome and baseline eGFR below 60 mL/min/1.73m2, icosapent ethyl cut time to first...
Cytokinetics Reveals New MAPLE-HCM Data at ESC Congress 2025
Aficamten improved peak oxygen uptake by a mean of 1.1 mL/kg/min at 24 weeks, while metoprolol declined by 1.2...
Interim Data for Pediatric HCM from Tenaya’s MyCLIMB Study
Interim data from Tenaya’s MyClimb natural history study of MYBPC3-associated pediatric HCM reported a 93% prevalence of nonobstructive disease...
Upstream Bio to Report Verekitug Phase 2 Top-Line Data
Upstream Bio will release top-line results tomorrow from VIBRANT, its global, randomized, placebo-controlled Phase 2 trial of verekitug in...